Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Castle Bio Prices IPO at $16 per Share

Castle Bio Prices IPO at $16 per Share

Jul 25, 2019
|
staff reporter

NEW YORK — Skin cancer test developer Castle Biosciences said today that it has priced its planned initial public offering at $16 a share, the top end of the previously disclosed range.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

What's Popular?

In Molecular Diagnostics

  1. Bio-Rad, United Biomedical Get FDA Emergency Use Authorizations for Coronavirus Tests

  2. Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M

  3. CMS Finalizes Blood-Based Colon Cancer Screening NCD with Non-Coverage for Epi ProColon

  4. JP Morgan Healthcare Conference, Day 3: Exact Sciences, Luminex, Danaher, Siemens Healthineers, and More

  5. Jonathan Rothberg-Led Startup Looks to Bring Disposable POC SARS-CoV-2 Test to Market

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.